News Archives

January 24, 2023

CLL Society’s COVID-19 Update for the Week of January 23, 2023

Here is your weekly summary of what has been happening this past week of January 23, 2023 in the United States.

January 19, 2023

Zanubrutinib Approved in the U.S. for Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL / SLL)

With the FDA’s approval of zanubrutinib, CLL / SLL patients have another very strong choice to manage their disease.

January 16, 2023

CLL Society’s COVID-19 Update for the Week of January 16, 2023

Here is your weekly summary of what has been happening this past week of January 16, 2023 in the United States.

January 13, 2023

The Changing Face of COVID-19: What it Means for the Immunocompromised

As much of the world has seemingly moved on from COVID-19 despite the ongoing global health emergency, the virus continues to pose serious risks for those who are immunocompromised.

January 13, 2023

Dr. Shahzad Mustafa on What it Means to be Immunocompromised for Those with CLL / SLL

\In this interview, Dr. Brian Koffman spoke with Dr. Shahzad Mustafa, Division Chief of Allergy, Immunology, and Rheumatology at Rochester Regional Health and Clinical Associate Professor of Medicine at the University of Rochester School of Medicine and Dentistry. They discussed immune deficiency (a.k.a. being immunocompromised) and what that means

January 10, 2023

High-Titer COVID-19 Convalescent Plasma as a Treatment Option for Those Who Are Immunocompromised After Becoming Infected with COVID-19

Those immunocompromised and/or immunosuppressed (IC/IS) who become infected with COVID-19 have always been at higher risk for hospitalization, ICU admission, and death throughout the pandemic.

January 9, 2023

CLL Society’s COVID-19 Update for the Week of January 9, 2023

Please read this week’s January 9, 2023 update which is pertinent to all of those who are immunocompromised, including anyone living with CLL / SLL regardless of treatment status.

January 6, 2023

ASH 2022: Dr. Carsten Niemann with an Update on Fixed-Duration Ibrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia (CLL) in the GLOW Study

Fixed-duration ibrutinib plus venetoclax provides an overall survival advantage and better sustained progression-free survival regardless of measurable residual disease (MRD) status compared with chlorambucil plus obinutuzumab as a first-line treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

January 6, 2023

ASH 2022: Dr. Christine Ryan on Triple Combination Acalabrutinib, Venetoclax, and Obinutuzumab for High-Risk Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL / SLL)

In this ongoing trial, the triple combination therapy with acalabrutinib, venetoclax, and obinutuzumab is highly active and has thus far produced durable remissions as a frontline treatment in patients with TP53-aberrant chronic lymphocytic leukemia (CLL), which was generally well tolerated with a low 2.9% incidence of atrial fibrillation with

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

News

CLL Society’s COVID-19 Update for the Week of January 23, 2023

Zanubrutinib Approved in the U.S. for Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL / SLL)

CLL Society’s COVID-19 Update for the Week of January 16, 2023

The Changing Face of COVID-19: What it Means for the Immunocompromised

Dr. Shahzad Mustafa on What it Means to be Immunocompromised for Those with CLL / SLL

High-Titer COVID-19 Convalescent Plasma as a Treatment Option for Those Who Are Immunocompromised After Becoming Infected with COVID-19

CLL Society’s COVID-19 Update for the Week of January 9, 2023

ASH 2022: Dr. Carsten Niemann with an Update on Fixed-Duration Ibrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia (CLL) in the GLOW Study

ASH 2022: Dr. Christine Ryan on Triple Combination Acalabrutinib, Venetoclax, and Obinutuzumab for High-Risk Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL / SLL)

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT